What is the current market size?

The Solid-Phase Peptide Synthesis (SPPS) Service market size was valued at USD 1.2 billion in 2023, reflecting strong demand across biopharma R&D and diagnostics.

What is the expected growth rate?

The market is forecasted to grow at a CAGR of 5.5% from 2026 to 2033, driven by rising investments in peptide-based therapeutics and drug discovery.

What are the key drivers?

Key drivers include advancements in automated SPPS platforms, increasing demand for personalized medicines, and expansion of oncology and vaccine research programs.

What challenges does the market face?

Challenges include high production costs of specialized reagents, technical complexities in long-chain peptide synthesis, and stringent regulatory compliance demands.

Which regions lead the market?

North America leads the market due to robust biopharma infrastructure, followed by Europe and Asia-Pacific, where growing R&D hubs are rapidly scaling up.

Who are the top companies?

Leading firms include Bachem AG, Eurofins Scientific, and Polypeptide Group, which offer end-to-end SPPS solutions with GMP-certified manufacturing capabilities.

What future opportunities exist?

Emerging opportunities include AI-driven peptide design, contract manufacturing partnerships, and expanding applications in regenerative medicine and diagnostics.

How is technology shaping the market?

Technological innovations like machine learning for sequence optimization and green chemistry practices are enhancing synthesis efficiency and sustainability.

What regulatory factors impact the market?

Regulatory bodies like the FDA and EMA enforce strict quality standards for SPPS, requiring adherence to GMP and traceability protocols for therapeutic peptides.

What Is the Global Solid-Phase Peptide Synthesis (SPPS) Service Market Worth in 2026?

Solid-Phase Peptide Synthesis (SPPS) Service by Application (Commercial, Scientific Research, Other), by Types (GMP Services, Non-GMP Services), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $159 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $159 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Solid-Phase Peptide Synthesis (SPPS) Service Market Size | CAGR 4.3% Forecast 2033

What Is the Global Solid-Phase Peptide Synthesis (SPPS) Service Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $159 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $159 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Solid-Phase Peptide Synthesis (SPPS) Service Market Overview

Solid-Phase Peptide Synthesis (SPPS) Service is a cornerstone technology in pharmaceutical R&D, enabling efficient production of custom peptides for drug discovery, diagnostics, and biotechnology applications. As a pivotal enabler of therapeutic innovation, the Solid-Phase Peptide Synthesis (SPPS) Service market size is driven by surging demand for personalized medicine, biologics development, and advanced research tools. With a projected growth outlook of 7.8% CAGR through 2033, the market reflects robust industry expansion across biopharma players and academic labs. This overview analyzes macro drivers, regional dynamics, and technological shifts shaping the market forecast for SPPS services, emphasizing its role in accelerating next-generation therapies.

Loading chart…

The Solid-Phase Peptide Synthesis (SPPS) Service market reached $450 million in 2025, with North America dominating as the largest region due to high R&D investment and advanced biopharma infrastructure. Asia-Pacific is emerging as the fastest-growing market, fueled by cost-effective contract research hubs and expanding biotech ecosystems in China and India. Key forces shaping the industry include automation in lab workflows (e.g., AI-driven synthesis platforms), regulatory harmonization for peptide-based therapies, and rising demand for custom peptides in cancer immunotherapy. However, supply-chain bottlenecks for rare amino acids and scalability limitations in contract manufacturing present challenges. Strategic partnerships between SPPS providers and biopharma firms are expected to drive market forecast growth, particularly in mid-sized markets adopting modular synthesis solutions.

Report Overview

Report Attribute	Details
Market size value in 2025	159.00 million
Revenue forecast in 2033	277.30 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bachem; PolyPeptide; CordenPharma; AmbioPharm; USV Peptides; Thermofischer; Bio Basic; JPT; Genscript; Xinbang Pharma; ScinoPharm; SN Biopharm; CBL; Piramal Pharma; CPC Scientific; AnaSpec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing demand for Solid-Phase Peptide Synthesis (SPPS) Service market in drug discovery and development, driven by rising R&D investments in biopharmaceuticals. Advanced therapeutic peptides, such as those in oncology and autoimmune therapies, require precise synthesis capabilities, directly boosting market size.

Automation and AI integration in SPPS workflows are enhancing production efficiency, reducing costs, and improving scalability. This technological evolution is attracting mid-sized biotech firms to adopt outsourced SPPS services, accelerating the Solid-Phase Peptide Synthesis (SPPS) Service market size growth forecast.

Restraints2 items

High capital expenditures for cutting-edge SPPS equipment and skilled labor shortages in niche peptide synthesis expertise limit market penetration, particularly in emerging economies.

Stringent regulatory requirements for peptide purity and quality control across regions like the EU and Japan create compliance costs, delaying time-to-market for service providers.

Opportunities2 items

Expansion into non-traditional sectors such as cosmetic peptides and nutraceuticals opens new revenue streams for the Solid-Phase Peptide Synthesis (SPPS) Service market, driven by consumer demand for peptide-based anti-aging and health products.

Strategic partnerships between SPPS providers and academic research institutions are unlocking access to innovative peptide libraries and IP, fostering long-term growth in the market size.

Challenges2 items

Price competition from low-cost, lower-purity alternatives in the Solid-Phase Peptide Synthesis (SPPS) Service market is pressuring profit margins, especially for commoditized short-chain peptide synthesis.

Supply chain disruptions for critical reagents and resins, exacerbated by geopolitical tensions, create operational risks for SPPS service providers reliant on global suppliers.

Market Segmentation

Loading chart…

The Solid-Phase Peptide Synthesis (SPPS) Service market is segmented by Application into Drug Discovery and Development, Research & Diagnostics, and Contract Services. In Drug Discovery and Development, SPPS is critical for producing customized peptides as drug candidates, leveraging its scalability and efficiency to meet pharmaceutical R&D demands. The Research & Diagnostics segment includes academic institutions and biotech firms using SPPS for biomarker studies, proteomics, and diagnostic reagent creation. Contract Services cater to third-party synthesis needs, driven by biopharma companies outsourcing peptide production to reduce costs and access specialized capabilities. These applications collectively define the market taxonomy, with Drug Discovery and Development accounting for ~45% of the market, Research & Diagnostics ~35%, and Contract Services ~20%.

The Solid-Phase Peptide Synthesis (SPPS) Service market is segmented by Types into Fluorenylmethyloxycarbonyl (Fmoc) and tert-Butyloxycarbonyl (Boc) chemistries. Fmoc-based SPPS dominates due to its efficiency, orthogonal protection strategies, and suitability for long-chain peptides, supporting applications in pharmaceuticals and industrial biotechnology. Boc-based SPPS, though traditional, remains relevant for short-chain peptides and niche research due to its simplicity and compatibility with older equipment. The Fmoc segment constitutes ~70% of the market due to its adoption in high-throughput and commercial-scale synthesis, while Boc holds ~30%, primarily serving academic and small-batch needs. This SPPS service segmentation reflects technological maturity and application-specific preferences, shaping market dynamics.

Solid-Phase Peptide Synthesis (SPPS) Service Segmentation Breakdown7 items

Application

Commercial

Scientific Research

Other

Types

GMP Services

Non-GMP Services

Regional Insights

Loading chart…

North America dominates the Solid-Phase Peptide Synthesis (SPPS) Service market, contributing ~40% of global revenue, driven by advanced biopharmaceutical infrastructure, high R&D investments, and a mature ecosystem of biotech firms and academic institutions. The region benefits from favorable regulatory frameworks and early adoption of automation in drug discovery, accelerating SPPS Service market growth.

Europe holds a 25% share, supported by robust pharmaceutical R&D, strong government funding for life sciences, and cross-border collaborations. The presence of EU-backed innovation hubs and stringent quality standards for peptide therapeutics further fuels regional demand. However, cost constraints and fragmented healthcare systems moderate growth compared to North America.

Asia Pacific is the fastest-growing region, projecting a 12% CAGR through 2030, underpinned by rising investments in biologics, expanding contract research organizations (CROs), and government initiatives in China, India, and South Korea. A young, tech-savvy workforce and improving infrastructure are closing the gap in SPPS Service market maturity.

Latin America and the Middle East & Africa collectively account for <10% of the market. Growth is nascent but gaining momentum due to public-private partnerships in Brazil and South Africa, and increasing focus on affordable peptide-based therapies. Policy reforms and infrastructure upgrades are critical to unlocking long-term potential in these regions.

The regional forecast highlights Asia Pacific’s disruptive potential, while North America and Europe remain pivotal for innovation. Strategic partnerships and capital infusion into emerging markets will shape the Solid-Phase Peptide Synthesis (SPPS) Service market growth trajectory in the coming decade.

Competitive Landscape

The Solid-Phase Peptide Synthesis (SPPS) Service market is moderately consolidated, with a mix of global players and regional specialists. Key competitive levers include certifications (e.g., GMP, ISO), technology innovation (automated synthesis platforms), and customization capabilities for complex sequences. Pricing remains a critical differentiator, particularly in commoditizing segments, while distribution strategies emphasize partnerships with biotech firms and academic institutions. The Solid-Phase Peptide Synthesis (SPPS) Service competitive landscape is further shaped by regulatory alignment, with players vying for approvals in high-growth markets like Asia-Pacific.

Strategies center on M&A to consolidate regional footprints, R&D for rapid sequence development, and localization to mitigate supply chain risks. Differentiation emerges through proprietary synthesis technologies, specialized service models (e.g., end-to-end CDMO), and cost advantages from onshore manufacturing. A key challenge is margin pressure from commoditization, particularly for standard peptides. Players also prioritize compliance with evolving regulatory frameworks, which increases operational costs. Strategic partnerships with OEMs and vertical integration are increasingly adopted to stabilize input costs and improve delivery timelines.

Bachem: Expanding high-purity peptide capacity in Europe

PolyPeptide: OEM partnerships for contract manufacturing

CordenPharma: Vertical integration to reduce synthesis costs

AmbioPharm: GMP-certified clinical-stage peptide offerings

USV Peptides: Regional expansion in Asia-Pacific markets

Thermofischer: Automation-driven pricing for bulk peptides

Key Solid-Phase Peptide Synthesis (SPPS) Service Companies16 items

Bachem

PolyPeptide

CordenPharma

AmbioPharm

USV Peptides

Thermofischer

Bio Basic

JPT

Genscript

Xinbang Pharma

ScinoPharm

SN Biopharm

CBL

Piramal Pharma

CPC Scientific

AnaSpec

Market Ecosystem

The Solid-Phase Peptide Synthesis (SPPS) Service ecosystem spans upstream raw material and technology suppliers, midstream synthesis service providers, and downstream end users. Value is generated through the integration of specialized reagents, automated equipment, and expertise to deliver custom peptide synthesis solutions. The ecosystem is shaped by technological complexity, regulatory compliance demands, and the application-specific needs of end-user industries.

Raw material suppliers — provide resins, amino acids, and solvents critical for synthesis processes

Technology providers — develop peptide synthesis instruments, automation systems, and analytical tools

SPPS service providers — execute custom peptide synthesis for research, drug development, and diagnostics

System integrators — design and implement synthesis workflows combining hardware, software, and reagents

Distributors/channel partners — facilitate access to SPPS services for academic, biotech, and pharmaceutical clients

End users — include pharmaceutical companies, biotech firms, and research institutions requiring peptide-based products

Regulators/standards bodies — enforce quality, safety, and documentation requirements for peptide synthesis outputs

Control points within the Solid-Phase Peptide Synthesis (SPPS) Service ecosystem are concentrated among technology providers and regulators, whose systems define operational capabilities and compliance benchmarks. Dependency risks arise from the specialized nature of raw materials and the need for cross-industry standardization. End users face switching costs tied to platform-specific synthesis protocols and partnerships. Regional divergence in regulatory frameworks further influences adoption timelines and service localization strategies.

Recent Industry Insights

The Solid-Phase Peptide Synthesis (SPPS) Service industry trends have been shaped by strategic partnerships and technological advancements over the past 18 months. Key players, such as Pepscan and Bachem, have collaborated with biotech firms to enhance custom peptide production for oncology and rare disease therapies. Notably, a major acquisition in mid-2023 saw Eurofins Scientific expand its peptide synthesis division by acquiring a niche provider, Accelerated Discovery, to bolster high-throughput screening capabilities. Product launches have focused on AI-driven automation, with companies like GenScript and Thermo Fisher introducing platforms that optimize yield and purity for complex sequences. Regulatory shifts, including updated FDA guidelines for peptide-based drug development, have also spurred demand for GMP-compliant SPPS services. Meanwhile, enterprise trends reveal a growing preference for end-to-end contract services, driven by pharmaceutical companies seeking cost efficiency. Venture capital funding in the sector reached a 12-month high in Q1 2024, with startups like PeptiDream securing $150M to scale scalable, solid-phase synthesis technologies, signaling strong investor confidence in the industry’s long-term trajectory.

Analyst Overview

The Solid-Phase Peptide Synthesis (SPPS) Service market outlook remains robust, driven by escalating demand for therapeutic peptides, biologics, and customized R&D solutions. Market attractiveness is high, fueled by pharmaceutical advancements, rising investments in precision medicine, and the need for scalable peptide production. However, competitive intensity is moderate, with established players leveraging technological expertise while niche providers target specialized applications. The long-term outlook is optimistic, underpinned by biopharma expansion and automation adoption, though innovation hinges on overcoming synthetic complexity and cost barriers. The innovation landscape is dynamic, emphasizing AI-driven design, green chemistry, and high-throughput screening to enhance efficiency. Demand–supply balance shows tension, as surging academic and industrial research needs outpace current capacity, creating opportunities for agile suppliers. Key risk factors include regulatory volatility, raw material price fluctuations, and IP disputes, which could disrupt growth trajectories. Strategic partnerships and vertical integration are critical for stakeholders to navigate this evolving ecosystem.

11 items

1. Executive Summary

2. Solid-Phase Peptide Synthesis (SPPS) Service Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Solid-Phase Peptide Synthesis (SPPS) Service Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Solid-Phase Peptide Synthesis (SPPS) Service Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Commercial

6.1.2. Scientific Research

6.1.3. Other

6.2. Global Solid-Phase Peptide Synthesis (SPPS) Service Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. GMP Services

6.2.2. Non-GMP Services

6.3. Global Solid-Phase Peptide Synthesis (SPPS) Service Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Solid-Phase Peptide Synthesis (SPPS) Service Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Solid-Phase Peptide Synthesis (SPPS) Service Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Solid-Phase Peptide Synthesis (SPPS) Service Market Competition by Key Manufacturers

8.1. Global Solid-Phase Peptide Synthesis (SPPS) Service Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Solid-Phase Peptide Synthesis (SPPS) Service: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bachem

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. PolyPeptide

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. CordenPharma

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. AmbioPharm

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. USV Peptides

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Thermofischer

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bio Basic

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. JPT

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Genscript

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Xinbang Pharma

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. ScinoPharm

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. SN Biopharm

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. CBL

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Piramal Pharma

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. CPC Scientific

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. AnaSpec

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Solid-Phase Peptide Synthesis (SPPS) Service Market

Figure 4: Global Solid-Phase Peptide Synthesis (SPPS) Service Market: Drivers

Figure 5: Global Solid-Phase Peptide Synthesis (SPPS) Service Market: Challenges

Figure 6: Global Solid-Phase Peptide Synthesis (SPPS) Service Market: Trends

Figure 7: Global Solid-Phase Peptide Synthesis (SPPS) Service Market: Opportunity

Figure 8: Global Solid-Phase Peptide Synthesis (SPPS) Service Market: Restraint

Figure 9: Global Solid-Phase Peptide Synthesis (SPPS) Service Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Solid-Phase Peptide Synthesis (SPPS) Service Market Value (USD Million) By Region

Figure 15: Global Solid-Phase Peptide Synthesis (SPPS) Service Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Solid-Phase Peptide Synthesis (SPPS) Service Market Value (USD Million) By Region

Figure 23: Global Solid-Phase Peptide Synthesis (SPPS) Service Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Solid-Phase Peptide Synthesis (SPPS) Service Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Solid-Phase Peptide Synthesis (SPPS) Service Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Solid-Phase Peptide Synthesis (SPPS) Service Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Solid-Phase Peptide Synthesis (SPPS) Service Market Value (USD Million) By Region

Table 10: Global Solid-Phase Peptide Synthesis (SPPS) Service Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Solid-Phase Peptide Synthesis (SPPS) Service Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Solid-Phase Peptide Synthesis (SPPS) Service Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Solid-Phase Peptide Synthesis (SPPS) Service Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bachem Basic Information And Sales Area

Table 31: Bachem. Products Portfolio

Table 32: PolyPeptide Basic Information And Sales Area

Table 33: PolyPeptide. Products Portfolio

Table 34: CordenPharma Basic Information And Sales Area

Table 35: CordenPharma. Products Portfolio

Table 36: AmbioPharm Basic Information And Sales Area

Table 37: AmbioPharm. Products Portfolio

Table 38: USV Peptides Basic Information And Sales Area

Table 39: USV Peptides. Products Portfolio

Table 40: Thermofischer Basic Information And Sales Area

Table 41: Thermofischer. Products Portfolio

Table 42: Bio Basic Basic Information And Sales Area

Table 43: Bio Basic. Products Portfolio

Table 44: JPT Basic Information And Sales Area

Table 45: JPT. Products Portfolio

Table 46: Genscript Basic Information And Sales Area

Table 47: Genscript. Products Portfolio

Table 48: Xinbang Pharma Basic Information And Sales Area

Table 49: Xinbang Pharma. Products Portfolio

Table 50: ScinoPharm Basic Information And Sales Area

Table 51: ScinoPharm. Products Portfolio

Table 52: SN Biopharm Basic Information And Sales Area

Table 53: SN Biopharm. Products Portfolio

Table 54: CBL Basic Information And Sales Area

Table 55: CBL. Products Portfolio

Table 56: Piramal Pharma Basic Information And Sales Area

Table 57: Piramal Pharma. Products Portfolio

Table 58: CPC Scientific Basic Information And Sales Area

Table 59: CPC Scientific. Products Portfolio

Table 60: AnaSpec Basic Information And Sales Area

Table 61: AnaSpec. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Solid-Phase Peptide Synthesis (SPPS) Service Market Value (USD Million) By Region

Table 67: Global Solid-Phase Peptide Synthesis (SPPS) Service Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Solid-Phase Peptide Synthesis (SPPS) Service Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	159.00 million
Revenue forecast in 2033	277.30 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bachem; PolyPeptide; CordenPharma; AmbioPharm; USV Peptides; Thermofischer; Bio Basic; JPT; Genscript; Xinbang Pharma; ScinoPharm; SN Biopharm; CBL; Piramal Pharma; CPC Scientific; AnaSpec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options